ArticleRadiation oncology (London, England)2024
Dose prediction of CyberKnife Monte Carlo plan for lung cancer patients based on deep learning: robust learning of variable beam configurations.
Article in Radiation oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Deep learning-based dose prediction for stereotactic prostate cancer radiotherapy with CyberKnife.Journal of applied clinical medical physics · 2026Article
- Prescription‑dose stratification improves deep learning‑based VMAT dose prediction in locally advanced NSCLC.Scientific reports · 2026Article
- A universal framework for IMRT dose prediction.Medical physics · 2026Article
- A glimpse into the CyberKnife robotic radiosurgery system: technical specifications and developments during thirty years.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAccurate calculation of lung cancer dose using the Monte Carlo (MC) algorithm in CyberKnife (CK) is essential for precise planning. We aim to employ deep learning to directly predict the 3D dose distribution calculated by the MC algorithm, enabling rapid and accurate automatic planning. However, most current methods solely focus on conventional intensity-modulated radiation therapy and assume a consistent beam configuration across all patients. This study seeks to develop a more versatile model incorporating variable beam configurations of CK and considering the patient's anatomy.
methodsThis study proposed that the AB (anatomy and beam) model be compared with the control Mask (only anatomy) model. These models are based on a 3D U-Net network to investigate the impact of CK beam encoding information on dose prediction. The study collected 86 lung cancer patients who received CK's built-in MC algorithm plans using different beam configurations for training/validation (66 cases) and testing (20 cases). We compared the gamma passing rate, dose difference maps, and relevant dose-volume metrics to evaluate the model's performance. In addition, the Dice similarity coefficients (DSCs) were calculated to assess the spatial correspondence of isodose volumes.
resultsThe AB model demonstrated superior performance compared to the Mask model, particularly in the trajectory dose of the beam. The DSCs of the AB model were 20-40% higher than that of the Mask model in some dose regions. We achieved approximately 99% for the PTV and generally more than 95% for the organs at risk (OARs) referred to the clinical planning dose in the gamma passing rates (3 mm/3%). Relative to the Mask model, the AB model exhibited more than 90% improvement in small voxels (p < 0.001). The AB model matched well with the clinical plan's dose-volume histograms, and the average dose error for all organs was 1.65 ± 0.69%.
conclusionsOur proposed new model signifies a crucial advancement in predicting CK 3D dose distributions for clinical applications. It enables planners to rapidly and precisely predict MC doses for lung cancer based on patient-specific beam configurations and optimize the CK treatment process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.